SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-005046
Filing Date
2024-02-06
Accepted
2024-02-06 09:20:38
Documents
19
Period of Report
2024-02-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 42802
2 ex5-1.htm EX-5.1 13821
3 ex10-1.htm EX-10.1 89354
4 ex99-1.htm EX-99.1 17575
5 ex5-1_001.jpg GRAPHIC 6342
6 ex99-1_001.jpg GRAPHIC 14063
  Complete submission text file 0001493152-24-005046.txt   393370

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE lctx-20240206.xsd EX-101.SCH 3024
8 XBRL LABEL FILE lctx-20240206_lab.xml EX-101.LAB 34240
9 XBRL PRESENTATION FILE lctx-20240206_pre.xml EX-101.PRE 22365
20 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3601
Mailing Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390
Lineage Cell Therapeutics, Inc. (Filer) CIK: 0000876343 (see all company filings)

IRS No.: 943127919 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12830 | Film No.: 24598315
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)